{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:54:30Z","timestamp":1762980870377,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Lysosomal acid lipase deficiency (LALD) is an autosomal recessive inborn error of lipid metabolism characterized by impaired lysosomal hydrolysis and consequent accumulation of cholesteryl esters and triglycerides. The phenotypic spectrum is diverse, ranging from severe, neonatal onset failure to thrive, hepatomegaly, hepatic fibrosis, malabsorption and adrenal insufficiency to childhood-onset hyperlipidemia, hepatomegaly, and hepatic fibrosis. Sebelipase alfa enzyme replacement has been approved by the Food and Drug Administration for use in LALD after demonstrating dramatic improvement in transaminitis and dyslipidemia with initiation of enzyme replacement therapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A chart review was performed on 2 patients with childhood-onset, symptomatic LALD with persistent dyslipidemia despite appropriate enzyme replacement therapy to identify biological pathways and risk factors for incomplete response to therapy.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Two patients with attenuated, symptomatic LALD had resolution of transaminitis on enzyme replacement therapy without concomitant effect on dyslipidemia despite dose escalation and no evidence of antibody response to enzyme.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Enzyme replacement therapy does not universally resolve all complications of LALD. Persistent dyslipidemia remains a clinically significant issue, likely related to the complex metabolic pathways implicated in LALD pathogenesis. We discuss the possible mechanistic basis for this unexpected finding and the implications for curative LALD therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-020-1328-6","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T13:22:45Z","timestamp":1583500965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Persistent dyslipidemia in treatment of lysosomal acid lipase deficiency"],"prefix":"10.1186","volume":"15","author":[{"given":"Amanda Barone","family":"Pritchard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alanna","family":"Strong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8331-9804","authenticated-orcid":false,"given":"Can","family":"Ficicioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"1328_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/sj.bmt.1702557","volume":"26","author":"W Krivit","year":"2000","unstructured":"Krivit W, Peters C, Dusenbery K, et al. Wolman disease successfully treated by bone marrow transplantation. Bone Marrow Transplant. 2000;26:567\u201370.","journal-title":"Bone Marrow Transplant"},{"key":"1328_CR2","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.jhep.2013.02.014","volume":"58","author":"DL Bernstein","year":"2013","unstructured":"Bernstein DL, Hulkova H, Bialer MG, Desnick RJ. Cholesteryl ester storage disease: review of the findings in 135 reported patients with an underdiagnosed disease. J Hepatol. 2013;58:1230\u201343.","journal-title":"J Hepatol"},{"key":"1328_CR3","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1016\/S0021-9258(19)40786-2","volume":"250","author":"JL Goldstein","year":"1975","unstructured":"Goldstein JL, Dana SE, Faust JR, Beaudet AL, Brown MS. Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease. J Biol Chem. 1975;250:8487\u201395.","journal-title":"J Biol Chem"},{"key":"1328_CR4","doi-asserted-by":"publisher","first-page":"30624","DOI":"10.1074\/jbc.M111.274381","volume":"286","author":"KL Bowden","year":"2011","unstructured":"Bowden KL, Bilbey NJ, Bilawchuk LM, et al. Lysosomal acid lipase deficiency impairs regulation of ABCA1 gene and formation of high density lipoproteins in cholesteryl ester storage disease. J Biol Chem. 2011;286:30624\u201335.","journal-title":"J Biol Chem"},{"key":"1328_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40256-017-0216-5","volume":"17","author":"JJ Maciejko","year":"2017","unstructured":"Maciejko JJ. Managing cardiovascular risk in Lysosomal acid lipase deficiency. Am J Cardiovasc Drugs. 2017;17:217\u201331.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1328_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40256-016-0203-2","volume":"16","author":"JE Frampton","year":"2016","unstructured":"Frampton JE. Sebelipase Alfa: a review in Lysosomal acid lipase deficiency. Am J Cardiovasc Drugs. 2016;16:461\u20138.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1328_CR7","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1056\/NEJMoa1501365","volume":"373","author":"BK Burton","year":"2015","unstructured":"Burton BK, Balwani M, Feillet F, et al. A phase 3 trial of Sebelipase Alfa in Lysosomal acid lipase deficiency. N Engl J Med. 2015;373:1010\u201320.","journal-title":"N Engl J Med"},{"key":"1328_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1006\/geno.1996.0162","volume":"33","author":"C Aslanidis","year":"1996","unstructured":"Aslanidis C, Ries S, Fehringer P, Buchler C, Klima H, Schmitz G. Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity. Genomics. 1996;33:85\u201393.","journal-title":"Genomics"},{"key":"1328_CR9","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jhep.2014.06.022","volume":"61","author":"V Valayannopoulos","year":"2014","unstructured":"Valayannopoulos V, Malinova V, Honzik T, et al. Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency. J Hepatol. 2014;61:1135\u201342.","journal-title":"J Hepatol"},{"key":"1328_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13023-017-0587-3","volume":"12","author":"SA Jones","year":"2017","unstructured":"Jones SA, Rojas-Caro S, Quinn AG, et al. Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study. Orphanet J Rare Dis. 2017;12:25.","journal-title":"Orphanet J Rare Dis"},{"key":"1328_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2017.08.021","volume":"265","author":"L Pisciotta","year":"2017","unstructured":"Pisciotta L, Tozzi G, Travaglini L, et al. Molecular and clinical characterization of a series of patients with childhood-onset lysosomal acid lipase deficiency. Retrospective investigations, follow-up and detection of two novel LIPA pathogenic variants. Atherosclerosis. 2017;265:124\u201332.","journal-title":"Atherosclerosis"},{"key":"1328_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jacl.2018.02.020","volume":"12","author":"DP Wilson","year":"2018","unstructured":"Wilson DP, Friedman M, Marulkar S, Hamby T, Bruckert E. Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency. J Clin Lipidol. 2018;12:604\u201314.","journal-title":"J Clin Lipidol"},{"key":"1328_CR13","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.clinthera.2015.06.004","volume":"37","author":"P Harmatz","year":"2015","unstructured":"Harmatz P. Enzyme replacement therapies and immunogenicity in Lysosomal storage diseases: is there a pattern? Clin Ther. 2015;37:2130\u20134.","journal-title":"Clin Ther"},{"key":"1328_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ymgme.2015.11.001","volume":"117","author":"PS Kishnani","year":"2016","unstructured":"Kishnani PS, Dickson PI, Muldowney L, et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab. 2016;117:66\u201383.","journal-title":"Mol Genet Metab"},{"key":"1328_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/TACG.S86760","volume":"9","author":"K Su","year":"2016","unstructured":"Su K, Donaldson E, Sharma R. Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa. Appl Clin Genet. 2016;9:157\u201367.","journal-title":"Appl Clin Genet"},{"key":"1328_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"CM Eng","year":"2001","unstructured":"Eng CM, Banikazemi M, Gordon RE, et al. A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet. 2001;68:711\u201322.","journal-title":"Am J Hum Genet"},{"key":"1328_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1086\/316953","volume":"68","author":"YA Ioannou","year":"2001","unstructured":"Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase a replacement in enzyme-deficient mice. Am J Hum Genet. 2001;68:14\u201325.","journal-title":"Am J Hum Genet"},{"key":"1328_CR18","doi-asserted-by":"publisher","first-page":"G836","DOI":"10.1152\/ajpgi.00243.2014","volume":"307","author":"A Aqul","year":"2014","unstructured":"Aqul A, Lopez AM, Posey KS, et al. Hepatic entrapment of esterified cholesterol drives continual expansion of whole body sterol pool in lysosomal acid lipase-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2014;307:G836\u201347.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1328_CR19","first-page":"500","volume":"2019","author":"C Leopold","year":"1864","unstructured":"Leopold C, Duta-Mare M, Sachdev V, et al. Hepatocyte-specific lysosomal acid lipase deficiency protects mice from diet-induced obesity but promotes hepatic inflammation. Biochim Biophys Acta Mol Cell Biol Lipids. 1864;2019:500\u201311.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"1328_CR20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1089\/104303402760128586","volume":"13","author":"H Du","year":"2002","unstructured":"Du H, Heur M, Witte DP, Ameis D, Grabowski GA. Lysosomal acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice. Hum Gene Ther. 2002;13:1361\u201372.","journal-title":"Hum Gene Ther"},{"key":"1328_CR21","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.ajpath.2015.05.021","volume":"185","author":"H Du","year":"2015","unstructured":"Du H, Zhao T, Ding X, Yan C. Hepatocyte-specific expression of human lysosome acid lipase corrects liver inflammation and tumor metastasis in lal (\u2212\/\u2212) mice. Am J Pathol. 2015;185:2379\u201389.","journal-title":"Am J Pathol"},{"key":"1328_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/jb\/mvj137","volume":"140","author":"O Zschenker","year":"2006","unstructured":"Zschenker O, Illies T, Ameis D. Overexpression of lysosomal acid lipase and other proteins in atherosclerosis. J Biochem. 2006;140:23\u201338.","journal-title":"J Biochem"},{"key":"1328_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/petr.12748","volume":"20","author":"S Sreekantam","year":"2016","unstructured":"Sreekantam S, Nicklaus-Wollenteit I, Orr J, et al. Successful long-term outcome of liver transplantation in late-onset lysosomal acid lipase deficiency. Pediatr Transplant. 2016;20:851\u20134.","journal-title":"Pediatr Transplant"},{"key":"1328_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/8904_2012_155","volume":"8","author":"GK Ambler","year":"2013","unstructured":"Ambler GK, Hoare M, Brais R, et al. Orthotopic liver transplantation in an adult with cholesterol ester storage disease. JIMD Rep. 2013;8:41\u20136.","journal-title":"JIMD Rep"},{"key":"1328_CR25","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0022-2275(20)33320-4","volume":"39","author":"E Sehayek","year":"1998","unstructured":"Sehayek E, Nath C, Heinemann T, et al. U-shape relationship between change in dietary cholesterol absorption and plasma lipoprotein responsiveness and evidence for extreme interindividual variation in dietary cholesterol absorption in humans. J Lipid Res. 1998;39:2415\u201322.","journal-title":"J Lipid Res"},{"key":"1328_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12944-017-0488-4","volume":"16","author":"CS Paththinige","year":"2017","unstructured":"Paththinige CS, Sirisena ND, Dissanayake V. Genetic determinants of inherited susceptibility to hypercholesterolemia - a comprehensive literature review. Lipids Health Dis. 2017;16:103.","journal-title":"Lipids Health Dis"},{"key":"1328_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/MOL.0000000000000159","volume":"26","author":"LA Lange","year":"2015","unstructured":"Lange LA, Willer CJ, Rich SS. Recent developments in genome and exome-wide analyses of plasma lipids. Curr Opin Lipidol. 2015;26:96\u2013102.","journal-title":"Curr Opin Lipidol"},{"key":"1328_CR28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nature09270","volume":"466","author":"TM Teslovich","year":"2010","unstructured":"Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707\u201313.","journal-title":"Nature"},{"key":"1328_CR29","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.bbrc.2013.12.096","volume":"443","author":"JC Chuang","year":"2014","unstructured":"Chuang JC, Lopez AM, Posey KS, Turley SD. Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease. Biochem Biophys Res Commun. 2014;443:1073\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1328_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bcp.2017.03.010","volume":"135","author":"JC Chuang","year":"2017","unstructured":"Chuang JC, Lopez AM, Turley SD. Quantitation of the rates of hepatic and intestinal cholesterol synthesis in lysosomal acid lipase-deficient mice before and during treatment with ezetimibe. Biochem Pharmacol. 2017;135:116\u201325.","journal-title":"Biochem Pharmacol"},{"key":"1328_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jacl.2016.11.008","volume":"11","author":"P Poinsot","year":"2017","unstructured":"Poinsot P, Collardeau Frachon S, Restier L, et al. Childhood\/adult-onset lysosomal acid lipase deficiency: a serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases. J Clin Lipidol. 2017;11:167\u201377 e3.","journal-title":"J Clin Lipidol"},{"key":"1328_CR32","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1172\/JCI113259","volume":"80","author":"HN Ginsberg","year":"1987","unstructured":"Ginsberg HN, Le NA, Short MP, Ramakrishnan R, Desnick RJ. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest. 1987;80:1692\u20137.","journal-title":"J Clin Invest"},{"key":"1328_CR33","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-2275(20)41416-6","volume":"33","author":"R Levy","year":"1992","unstructured":"Levy R, Ostlund RE Jr, Schonfeld G, Wong P, Semenkovich CF. Cholesteryl ester storage disease: complex molecular effects of chronic lovastatin therapy. J Lipid Res. 1992;33:1005\u201315.","journal-title":"J Lipid Res"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1328-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-1328-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-1328-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:25:18Z","timestamp":1614039918000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-1328-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1328"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-1328-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"20 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Need for IRB approval for this study was waived, as there were fewer than 5 participants. Patients and their families did consent for participation in this study and for its publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants and their families were consented for publication via email and telephone as witnessed by Alanna Strong.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}